×
About 509,578 results

Surgical Treatment of Levodopa-induced Dyskinesia in Parkinson's Disease
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC5586111/

The treatment of motor manifestations of Parkinson's disease (PD) is essentially a trade-off between adequate relief of motor symptoms and prevention and control of motor complications, particularly levodopa-induced dyskinesia (LID). Progression of PD is paralleled by a progressive difficulty in achieving the balance. Functional neurosurgical procedures provide sustained relief of LID in carefu...

KRd, VRd Equivalency in Multiple Myeloma ‘Reassuring’ to Hematologists
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200219/full/

Jun 23rd, 2020 - Awaited results of the ENDURANCE trial showed equivalency between a regimen of carfilzomib plus lenalidomide and dexamethasone (KRd) and bortezomib, lenalidomide, and dexamethasone (VRd) as an initial therapy for patients with standard- or intermediate-risk multiple myeloma (Abstract LBA3). KRd failed to improve progression-free survival compared with VRd, according to data presented by Shaji K...

The Impact of COVID-19 on Medical Education
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7193226/
Cureus

In the wake of the novel coronavirus (COVID-19) pandemic, it is abundantly clear to all the necessity of studying the pathology and widespread health consequences associated with the virus. However, what is much less clear is the impact of COVID-19 on medical education. Already, faculty and medical students are grappling with the changes that have been made and attempting to consolidate these w...

Lung ultrasound monitoring in patients with COVID-19 on home isolation
https://www.sciencedirect.com/science/article/pii/S073567572030440X

Many patients with COVID-19, the clinical illness caused by SARS-CoV-2 infection, exhibit mild symptoms and do not require hospitalization. Instead, these patients are often referred for 14-days of home isolation as symptoms resolve. Lung ultrasound is well-established as an important means of evaluating lung pathology in patients in the emergency department and in intensive care units. Ultraso...

Presynaptic mechanisms of l-DOPA-induced dyskinesia: the findings, the debate, and the therapeutic implications
https://www.frontiersin.org/articles/10.3389/fneur.2014.00242/full
Frontiers in Neurology;

Dec 14th, 2014 - The dopamine (DA) precursor l-DOPA has been the most effective treatment for Parkinson’s disease (PD) for over 40 years. However, the response to this treatment changes with disease progression, and most patients develop dyskinesias (abnormal involuntary movements) and motor fluctuations within a few years of l-DOPA therapy.

Metabotropic Glutamate Receptors for Parkinson's Disease Therapy
https://www.ncbi.nlm.nih.gov/pmc/articles/PMC3703788/
Parkinson's Disease;

May 28th, 2013 - Excessive glutamatergic signalling within the basal ganglia is implicated in the progression of Parkinson's disease (PD) and inthe emergence of dyskinesia associated with long-term treatment with L-DOPA. There is considerable research focus on the discovery and development of compounds that modulate glutamatergic signalling via glutamate receptors, as treatments for PD and L-DOPA-induced dyskin...

Michael S. Hofman, MBBS, on Prostate Cancer: LuPSMA vs Cabazitaxel in Metastatic Castration-Resistant Disease
https://ascopost.com/videos/asco20-virtual-scientific-program/michael-hofman-on-lupsma-vs-cabazitaxel-in-metastatic-castration-resistant-prostate-cancer/

May 29th, 2020 - Michael S. Hofman, MBBS, of the Peter MacCallum Cancer Centre, discusses phase II results from the ANZUP 1603 trial, which showed that in men with docetaxel-treated metastatic castration-resistant prostate cancer, LuPSMA was more active than cabazitaxel, with relatively fewer grade 3 and 4 adverse events and a more favorable PSA progression-free-survival (Abstract 5500).

David R. Wise, MD, PhD, on Novel Biomarkers in Prostate Cancer: Is Tissue the Issue?
https://ascopost.com/videos/asco20-virtual-scientific-program/david-wise-on-novel-biomarkers-in-prostate-cancer/

May 29th, 2020 - David R. Wise, MD, PhD, of New York University Perlmutter Cancer Center, summarizes three important studies in prostate cancer: circulating tumor cell count as a prognostic marker of PSA response and progression in metastatic castration-sensitive disease; new phenotypic subtypes; and how circulating tumor DNA dynamics associate with treatment response and radiologic progression-free survival (A...

First-Line Pembrolizumab Plus Etoposide/Platinum for Extensive-Stage Small Cell Lung Cancer
https://ascopost.com/news/may-2020/first-line-pembrolizumab-plus-etoposideplatinum-for-extensive-stage-small-cell-lung-cancer/

May 29th, 2020 - As reported at the ASCO20 Virtual Scientific Program by Charles M. Rudin, MD, PhD, and colleagues (Abstract 9001), the phase III KEYNOTE-604 trial has shown that first-line pembrolizumab plus etoposide/platinum significantly prolonged progression-free survival and prolonged overall survival at a near significant level vs placebo plus etoposide/platinum in patients with extensive-stage small cel...

Expert Point of View: Jonathan E. Rosenberg, MD
https://ascopost.com/news/may-2020/epov-jonathan-rosenberg/

May 27th, 2020 - “These data are solid, showing a 7-month improvement in overall survival in patients with stable disease or better after first-line chemotherapy. This is roughly a 50% improvement in survival, which is clinically meaningful. Also, progression-free survival was significantly increased with maintenance avelumab,” said Jonathan E. Rosenberg, MD, of Memorial Sloan Kettering Cancer Center in New Yor...

Pembrolizumab Monotherapy Demonstrates PFS Benefit Over Brentuximab Vedotin in Relapsed or Refractory Classical Hodgkin Lymphoma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200193/full/

May 28th, 2020 - Pembrolizumab monotherapy demonstrated a progression-free survival (PFS) benefit over brentuximab vedotin (BV) in patients with relapsed or refractory (R/R) classical Hodgkin lymphoma, according to the results from the phase III international KEYNOTE-204 trial (Abstract 8005). Clinically meaningful improvement in PFS was observed in all subgroups tested, including patients who did not receive a...

Selinexor/Bortezomib/Dexamethasone Triplet Improves PFS, ORR in Multiple Myeloma
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200181/full/

May 28th, 2020 - Once-weekly selinexor, bortezomib, and dexamethasone (SVd) for relapsed/refractory multiple myeloma (MM) significantly improved progression-free survival (PFS) and overall response rate (ORR) when compared with twice-weekly bortezomib and dexamethasone (Vd), according to initial results from the phase III BOSTON trial (Abstract 8501).

Triplet Combination Considered New Standard of Care for Patients With HER2-Positive Metastatic Breast Cancer, Brain Metastases
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200164/full/

May 28th, 2020 - Exploratory analyses conducted in a subset of heavily pretreated patients with brain metastases enrolled on the HER2CLIMB trial found that tucatinib in combination with trastuzumab and capecitabine reduces the risk of intracranial (IC) progression and death in patients with HER2-positive metastatic breast cancer (MBC; Abstract 1005). Nancy U. Lin, MD, of Dana-Farber Cancer Institute, presented ...

Upfront Radiation Added to TKI Therapy Improves Outcomes in Oligometastatic NSCLC
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200171/full/

May 28th, 2020 - The addition of stereotactic body radiation therapy (SBRT) to tyrosine kinase inhibitor (TKI) therapy yielded longer progression-free survival (PFS) and overall survival (OS) than TKI therapy alone in patients with EGFR-mutant oligometastatic non–small cell lung cancer (NSCLC), according to an interim analysis of an open-label phase III trial presented during the ASCO20 Virtual Scientific Progr...

https://dailynews.ascopubs.org/do/10.1200/ADN.20.200143/full/
https://dailynews.ascopubs.org/do/10.1200/ADN.20.200143/full/

May 19th, 2020 - In the phase III PROfound trial (NCT02987543), men with metastatic castration-resistant prostate cancer (mCRPC) who had disease progression while receiving enzalutamide or abiraterone and who had homologous recombination repair (HRR) gene alterations demonstrated longer progression-free survival and better measures of response when treated with olaparib than enzalutamide or abiraterone.1 Now, t...

Precision oncology approach confers clinical benefit in relapsed pediatric cancer
https://www.healio.com/hematology-oncology/pediatric-oncology/news/online/{c271560a-fc37-4dd7-988e-c31845918035}/precision-oncology-approach-confers-clinical-benefit-in-relapsed-pediatric-cancer

May 28th, 2020 - An algorithm designed to identify molecular targets for precision therapy extended time to disease progression for pediatric patients with relapsed cancer, according to study results presented during the ASCO20 Virtual Scientific Program.

Upfront pembrolizumab doubles PFS in MSI-H/dMMR metastatic colorectal cancer
https://www.mdedge.com/hematology-oncology/article/223031/gastroenterology/upfront-pembrolizumab-doubles-pfs-msi-h/dmmr

May 28th, 2020 - Frontline pembrolizumab doubled progression-free survival (PFS), when compared with chemotherapy, among patients with microsatellite instability–high/mismatch repair-deficient (MSI-H/dMMR) metastatic colorectal cancer in the KEYNOTE-177 study.

PFS Data Show Carfilzomib Triplet Remains Inferior to VRd in Newly Diagnosed Myeloma
https://www.targetedonc.com/view/pfs-data-show-carfilzomib-triplet-remains-inferior-to-vrd-in-newly-diagnosed-myeloma

May 28th, 2020 - Results from the ENDURANCE (E1A11) trial demonstrated that carfilzomib (Kyprolis), a next-generation proteasome inhibitor, in combination with lenalidomide (Revlimid), and dexamethasone (Decadron; KRd) failed to improve progression-free survival in patients with newly diagnosed myeloma compared with the standard-of-care regimen, bortezomib (Velcade) plus lenalidomide and dexamethasone (VRd), ac...

Pyrotinib bests lapatinib in HER2+ metastatic breast cancer
https://www.mdedge.com/hematology-oncology/article/223057/breast-cancer/pyrotinib-bests-lapatinib-her2-metastatic-breast

May 30th, 2020 - The combination of pyrotinib and capecitabine significantly prolonged progression-free survival (PFS), when compared with lapatinib and capecitabine, among patients with previously treated HER2-positive metastatic breast cancer in a phase 3 trial.

Pembrolizumab prolonged PFS vs. brentuximab vedotin in r/r Hodgkin lymphoma
https://www.mdedge.com/hematology-oncology/article/223065/hodgkin-lymphoma/pembrolizumab-prolonged-pfs-vs-brentuximab

May 31st, 2020 - Pembrolizumab treatment significantly improved progression-free survival versus brentuximab vedotin in a recent randomized, phase 3 trial including patients with relapsed or refractory classical Hodgkin lymphoma, an investigator has reported.